Antibodies, Viral

• 

  Subject Areas on Research

  • A Bivalent Omicron-Containing Booster Vaccine against Covid-19. 
  • A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses. 
  • A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity. 
  • A MUC16 IgG Binding Activity Selects for a Restricted Subset of IgG Enriched for Certain Simian Immunodeficiency Virus Epitope Specificities. 
  • A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface. 
  • A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. 
  • A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. 
  • A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. 
  • A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. 
  • A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. 
  • A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. 
  • A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. 
  • A comparison of serologic methods for diagnosis of Rocky Mountain spotted fever. 
  • A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. 
  • A feline immunodeficiency virus vif-deletion mutant remains attenuated upon infection of newborn kittens. 
  • A genetically engineered, stem-cell-derived cellular vaccine. 
  • A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. 
  • A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. 
  • A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody. 
  • A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. 
  • A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice. 
  • A novel, rapid assay for detection and differentiation of serotype-specific antibodies to Venezuelan equine encephalitis complex alphaviruses. 
  • A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). 
  • A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. 
  • A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. 
  • A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients. 
  • A seroepidemiological study of pandemic A/H1N1(2009) influenza in a rural population of Mali. 
  • A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged. 
  • A single genetic locus determines the efficacy of serum therapy against murine adenocarcinoma 755a. 
  • A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. 
  • A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. 
  • AIDS-related cytomegalovirus retinitis: lessons from the laboratory. 
  • ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. 
  • Absence of macrophage involvement in the passive serum therapy of Friend leukemia virus-induced disease. 
  • Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. 
  • Acquired immunodeficiency syndrome-like illness associated with systemic Mycoplasma fermentans infection in a human immunodeficiency virus-negative homosexual man. 
  • Acute leukemia in Burkitt lymphoma. 
  • Acute retinal necrosis after chickenpox in a patient with acquired immunodeficiency syndrome. 
  • Acute retinal necrosis following epidural steroid injections. 
  • Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. 
  • Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. 
  • Age-related patterns of cytomegalovirus antibodies accompanying Epstein-Barr virus co-infection. 
  • Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. 
  • Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. 
  • An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. 
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. 
  • An essential role of antibodies in the control of Chikungunya virus infection. 
  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. 
  • An outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. 
  • Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. 
  • Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. 
  • Anti-EBV serologic tests for nasopharyngeal carcinoma. 
  • Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. 
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. 
  • Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. 
  • Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. 
  • Anti-polyribosylribitol phosphate antibody levels 5 years after a primary series of Haemophilus influenzae type B conjugate vaccine. 
  • Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. 
  • Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. 
  • Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism. 
  • Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). 
  • Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. 
  • Antibodies, boosters, and optimizing SARS-CoV-2 vaccines for transplantation: A call for more research. 
  • Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. 
  • Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS). 
  • Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans. 
  • Antibody is critical for the clearance of murine norovirus infection. 
  • Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. 
  • Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? 
  • Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. 
  • Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. 
  • Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. 
  • Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. 
  • Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. 
  • Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. 
  • Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. 
  • Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. 
  • Antigen-specific T-lymphocyte function after cord blood transplantation. 
  • Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. 
  • Antiinflammatory proteins associated with human and murine neoplasms. 
  • Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. 
  • Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. 
  • Association of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome. 
  • Association of the human type C retrovirus with a subset of adult T-cell cancers. 
  • Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. 
  • Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. 
  • Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies. 
  • B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. 
  • BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. 
  • Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. 
  • Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. 
  • Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. 
  • Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques. 
  • Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. 
  • Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. 
  • CD4 T follicular helper cell dynamics during SIV infection. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. 
  • COVID-19 convalescent plasma. 
  • COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. 
  • Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. 
  • Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. 
  • Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Characterization of Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus. 
  • Characterization of Simian Immunodeficiency Virus Variants Anatomically Compartmentalized in Plasma and Milk in Chronically Infected African Green Monkeys. 
  • Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice. 
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. II. Response in C57BL/6 mice. 
  • Characterization of the immune response to the major glycoprotein (gp71) of Friend leukemia virus. III. Influence on endogenous MuLV-mediated pathogenesis. 
  • Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. 
  • Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania. 
  • Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. 
  • Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. 
  • Chimeric alphavirus vaccine candidates for chikungunya. 
  • Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. 
  • Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. 
  • Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. 
  • Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women. 
  • Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. 
  • Clonal isolate of the simian sarcoma virus codes for a Gag-related 65,000-dalton protein. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach. 
  • Cold sensitivity of the SARS-CoV-2 spike ectodomain. 
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. 
  • Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques. 
  • Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. 
  • Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. 
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. 
  • Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. 
  • Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. 
  • Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. 
  • Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. 
  • Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. 
  • Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. 
  • Congenital Human Cytomegalovirus Infection Is Associated With Decreased Transplacental IgG Transfer Efficiency Due to Maternal Hypergammaglobulinemia. 
  • Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. 
  • Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. 
  • Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. 
  • Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. 
  • Cross-Reactive Dengue Virus Antibodies Augment Zika Virus Infection of Human Placental Macrophages. 
  • Cross-Reactive Immunity Among Flaviviruses. 
  • Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. 
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. 
  • Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. 
  • Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. 
  • Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III). 
  • Cutaneous squamous cell carcinoma and human papillomavirus: is there an association? 
  • Cytokine expression in vivo during murine herpetic stromal keratitis. Effect of protective antibody therapy. 
  • Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. 
  • Cytomegalovirus infection and chronic hemodialysis. 
  • Cytomegalovirus infection in the normal host. 
  • Cytomegalovirus pericarditis: a case series and review of the literature. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. 
  • DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. 
  • DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020. 
  • Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. 
  • Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. 
  • Deployment of convalescent plasma for the prevention and treatment of COVID-19. 
  • Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor. 
  • Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay. 
  • Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification. 
  • Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. 
  • Determinants of the source of cytomegalovirus in murine renal allograft recipients. 
  • Determination of the cleavage site of enterovirus 71 VP0 and the effect of this cleavage on viral infectivity and assembly. 
  • Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. 
  • Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. 
  • Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques. 
  • Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG. 
  • Development of a monoclonal antibody specific for serotype 3 rotavirus strains. 
  • Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. 
  • Differential immune imprinting by influenza virus vaccination and infection in nonhuman primates. 
  • Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. 
  • Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. 
  • Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. 
  • Ebola virus antibody decay-stimulation in a high proportion of survivors. 
  • Ebola virus disease: implications for solid organ transplantation. 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. 
  • Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV. 
  • Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. 
  • Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. 
  • Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. 
  • Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. 
  • Effects of murine cytomegalovirus infection on the immune response to a tumor allograft. 
  • Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. 
  • Efficient transplacental IgG transfer in women infected with Zika virus during pregnancy. 
  • Electron tomography of viruses. 
  • Emergence of Epidemic Dengue-1 Virus in the Southern Province of Sri Lanka. 
  • Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. 
  • Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. 
  • Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. 
  • Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. 
  • Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. 
  • Epstein-Barr in acute nontraumatic mononeuropathies. 
  • Epstein-Barr virus antibodies in whole blood spots: a minimally invasive method for assessing an aspect of cell-mediated immunity. 
  • Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. 
  • Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. 
  • Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus. 
  • Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. 
  • Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications. 
  • Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children. 
  • Evaluation of an atypical HIV type 1 antibody. Serologic pattern leading to detection of HIV type 2 infection in North America. 
  • Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. 
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. 
  • Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model. 
  • Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories. 
  • Evidence against transmission of human T-lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV) in families of children with the acquired immunodeficiency syndrome. 
  • Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. 
  • Evidence for immune-mediated reduction of viral replication in Macaca nemestrina mucosally immunized with inactivated SHIV(89.6). 
  • Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses. 
  • Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies. 
  • Expression of a murine cytomegalovirus early-late protein in "latently" infected mice. 
  • Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors. 
  • Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. 
  • Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. 
  • Fatal cytomegalovirus bronchiolitis in a patient with Nezelof's syndrome. 
  • Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. 
  • GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. 
  • Geographic Disparities in Cytomegalovirus Infection During Pregnancy. 
  • Granulomatous hepatitis associated with acute cytomegalovirus infection. 
  • H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. 
  • H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. 
  • HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. 
  • HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. 
  • HIV-1: nature's master of disguise. 
  • HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. 
  • HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. 
  • HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. 
  • HTLV-III seroconversion associated with heat-treated factor VIII concentrate. 
  • HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. 
  • Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. 
  • Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. 
  • Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. 
  • Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. 
  • Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. 
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. 
  • High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques. 
  • High Risk of Influenza Virus Infection Among Swine Workers: Examining a Dynamic Cohort in China. 
  • High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. 
  • High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. 
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. 
  • High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. 
  • Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. 
  • Homologous and Heterologous Covid-19 Booster Vaccinations. 
  • How did we rapidly implement a convalescent plasma program? 
  • Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. 
  • Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. 
  • Human T-cell lymphotropic virus I and adult T-cell leukemia: report of a cluster in North Carolina. 
  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. 
  • Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. 
  • Human malignant and mitogen-transformed cells contain retroviral P15E-related antigen. 
  • Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. 
  • Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus. 
  • Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition. 
  • Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. 
  • Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. 
  • IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease. 
  • Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. 
  • IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. 
  • Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. 
  • Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. 
  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. 
  • Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. 
  • Immune correlates of protection for dengue: State of the art and research agenda. 
  • Immune correlates of vaccine protection against HIV-1 acquisition. 
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 
  • Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses. 
  • Immunity to varicella, measles, and mumps in patients evaluated for lung transplantation. 
  • Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. 
  • Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells. 
  • Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. 
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes. 
  • Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. 
  • Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. 
  • Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. 
  • Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies. 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • Impact of Vaccination With the SCB-2019 Coronavirus Disease 2019 Vaccine on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Household Contact Study in the Philippines. 
  • Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. 
  • Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. 
  • Impact of the genetic background of transgenic mice upon the formation and timing of choroid plexus papillomas. 
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. 
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. 
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. 
  • Improving SARS-CoV-2 structures: Peer review by early coordinate release. 
  • In the shadow of antibodies: how T cells defend against COVID-19. 
  • In vitro assays for detecting neutralizing and fusion-inhibiting antibodies to SIVMAC251. 
  • In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. 
  • Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. 
  • Inactivation of murine xenotropic oncornavirus by normal mouse sera is not immunoglobulin-mediated. 
  • Incidence of Herpesvirus hominis antibodies among blood donor populations. 
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. 
  • Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. 
  • Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. 
  • Individual and Spatial Risk of Dengue Virus Infection in Puerto Maldonado, Peru. 
  • Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. 
  • Induction of cytotoxic T cell responses in newborn mice by DNA immunization. 
  • Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. 
  • Infant Antibody Repertoires during the First Two Years of Influenza Vaccination. 
  • Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later. 
  • Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates. 
  • Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. 
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. 
  • Influence of antisera to oncornavirus glycoprotein (gp71) on infections of cats with feline leukemia virus. 
  • Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope. 
  • Influenza and Antibody-Dependent Cellular Cytotoxicity. 
  • Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. 
  • Influenza research in the Soviet Union--1974. 
  • Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses. 
  • Inter-epidemic Rift Valley fever virus infection incidence and risks for zoonotic spillover in northern Tanzania. 
  • Interferon Inhibition Enhances the Pilot-Scale Production of Rabies Virus in Human Diploid MRC-5 Cells. 
  • Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. 
  • In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. 
  • Kaposi's sarcoma in homosexual men-a report of eight cases. 
  • Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. 
  • Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. 
  • Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. 
  • Leptospirosis and human immunodeficiency virus co-infection among febrile inpatients in northern Tanzania. 
  • Lessons learned from HIV-1 vaccine trials: new priorities and directions. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques. 
  • Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. 
  • Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. 
  • Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. 
  • Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. 
  • Lower SARS-CoV-2-specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19. 
  • Mammalian C-type oncorna viruses. Relationships between structural virus and cell surface antigens and their possible significance in immunological defense mechanisms. 
  • Mammalian C-type oncornaviruses: relationships between viral structural and cell-surface antigens and their possible significance in immunological defense mechanisms. 
  • Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. 
  • Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. 
  • Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage. 
  • Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. 
  • Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection. 
  • Maternal Immunity and Vaccination Influence Disease Severity in Progeny in a Novel Mast Cell-Deficient Mouse Model of Severe Dengue. 
  • Maternal antibody interference contributes to reduced rotavirus vaccine efficacy in developing countries. 
  • Maternal immunity and antibodies to dengue virus promote infection and Zika virus-induced microcephaly in fetuses. 
  • Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies. 
  • Measles immunity in HIV-infected children. 
  • Measles virus nucleocapsids: large-scale purification and use in radioimmunoassays. 
  • Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires. 
  • Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. 
  • Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis. 
  • Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. 
  • Modified varicella-like syndrome in children previously vaccinated with live attenuated measles, mumps, rubella and varicella vaccine. 
  • Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • Monoclonal antibodies against human T cell leukemia-lymphoma virus (HTLV) p24 internal core protein. Use as diagnostic probes and cellular localization of HTLV. 
  • Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. 
  • Mucosal plasma cells are required to protect the upper airway and brain from infection. 
  • Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective. 
  • Multimodal assessments of Zika virus immune pathophysiological responses in marmosets. 
  • Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. 
  • Murine cytomegalovirus infection: hematological, morphological, and functional study of lymphoid cells. 
  • Murine malignant cells synthesize a 19,000-dalton protein that is physicochemically and antigenically related to the immunosuppressive retroviral protein, P15E. 
  • Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. 
  • Natural infection of a household pet red-capped mangabey (Cercocebus torquatus torquatus) with a new simian immunodeficiency virus. 
  • Neonate-primed CD8+ memory cells rival adult-primed memory cells in antigen-driven expansion and anti-viral protection. 
  • Neutralization epitopes of the HIV-1 primary isolate DH012. 
  • Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination. 
  • Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. 
  • Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. 
  • Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial. 
  • Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. 
  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. 
  • Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. 
  • Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. 
  • Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm). 
  • Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. 
  • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. 
  • Oncornavirus-like protein expression in human prostatic tissue. 
  • One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. 
  • Oral Coadministration of an Intramuscular DNA/Modified Vaccinia Ankara Vaccine for Simian Immunodeficiency Virus Is Associated with Better Control of Infection in Orally Exposed Infant Macaques. 
  • Outbreaks of acute gastroenteritis associated with Norwalk-like viruses in campus settings. 
  • Outcomes among children and adults at risk of severe dengue in Sri Lanka: Opportunity for outpatient case management in countries with high disease burden. 
  • PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs. 
  • Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. 
  • Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. 
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. 
  • Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. 
  • Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. 
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction. 
  • Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. 
  • Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. 
  • Persistent infection with neurotropic herpes viruses and cognitive impairment. 
  • Phage display screening for peptides that inhibit polyglutamine aggregation. 
  • Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. 
  • Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. 
  • Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. 
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. 
  • Phenotypic Correlates of HIV-1 Macrophage Tropism. 
  • Phenotypic characterization and ontogeny of components of the human thymic microenvironment. 
  • Placental Transfer of Respiratory Syncytial Virus Antibody Among HIV-Exposed, Uninfected Infants. 
  • Plasma Tryptophan and the Kynurenine-Tryptophan Ratio are Associated with the Acquisition of Statural Growth Deficits and Oral Vaccine Underperformance in Populations with Environmental Enteropathy. 
  • Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. 
  • Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. 
  • Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. 
  • Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. 
  • Porcine reproductive and respiratory syndrome virus induces pronounced immune modulatory responses at mucosal tissues in the parental vaccine strain VR2332 infected pigs. 
  • Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. 
  • Potential leukemia virus subunit vaccines: discussion. 
  • Pre-existing immunity to cytomegalovirus in macaques influences human CMV vaccine responses in preclinical models. 
  • Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. 
  • Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys. 
  • Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. 
  • Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York. 
  • Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. 
  • Prevalence of antibodies to rotavirus in different age-groups of infants in Bochum, West Germany. 
  • Prevalence of influenza A virus in live-captured North Atlantic gray seals: a possible wild reservoir. 
  • Prevalence of non-A, non-B hepatitis/hepatitis C virus antibody in laboratory quality-assurance sera. 
  • Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. 
  • Prevention of oncornavirus-induced sarcomas in cats by treatment with antiviral antibodies. 
  • Probable and possible transfusion-transmitted dengue associated with NS1 antigen-negative but RNA confirmed-positive red blood cells. 
  • Production of chemotactic factor and lymphotoxin by human leukocytes stimulated with Herpes simplex virus. 
  • Programming the magnitude and persistence of antibody responses with innate immunity. 
  • Progress in HIV-1 vaccine development. 
  • Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias. 
  • Properties of mouse leukemia viruses. XIX. Effective antibody therapy of AKR leukemia occurs independently of virus neutralization and produces long-term changes in the virus status of the thymus. 
  • Properties of mouse leukemia viruses. XVI. Suppression of spontaneous fetal leukemias in AKR mice by treatment with broadly reacting antibody against the viral glycoprotein gp 71. 
  • Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71. 
  • Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy. 
  • Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. 
  • Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. 
  • Prospects for prevention of and early intervention against HIV. 
  • Prospects for the immunological management of lethal tumors. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • Prostaglandin E2 production during neonatal respiratory infection with mouse adenovirus type 1. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. 
  • Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. 
  • Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. 
  • Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study. 
  • Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. 
  • Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood. 
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. 
  • Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 
  • Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. 
  • Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. 
  • Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. 
  • Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. 
  • Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites. 
  • Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques. 
  • Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. 
  • Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. 
  • Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. 
  • Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. 
  • Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. 
  • Reduction of peak viremia by an integration-defective SIV proviral DNA vaccine in rhesus macaques. 
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. 
  • Regulation of the B cell response to T-dependent antigens by classical pathway complement. 
  • Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. 
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. 
  • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. 
  • Requirement of MIP-1 alpha for an inflammatory response to viral infection. 
  • Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. 
  • Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. 
  • Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein. 
  • Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. 
  • Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. 
  • Reversible Reprogramming of Circulating Memory T Follicular Helper Cell Function during Chronic HIV Infection. 
  • RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines. 
  • Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. 
  • Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. 
  • Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome. 
  • Role of carbohydrate in biological functions of Friend murine leukemia virus gp71. 
  • Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection. 
  • SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. 
  • SARS-CoV-2 Antibody Serology Testing in a 3-Month-Old Organ Donor: A Case Report and Review of Available Literature. 
  • SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia. 
  • SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason. 
  • SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. 
  • SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. 
  • SARS-CoV-2 viral load is associated with increased disease severity and mortality. 
  • SIV infection duration largely determines broadening of neutralizing antibody response in macaques. 
  • SIV vaccine protection of rhesus monkeys. 
  • SIVcpz in wild chimpanzees. 
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. 
  • SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. 
  • Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age. 
  • Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. 
  • Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. 
  • Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. 
  • Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. 
  • Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. 
  • Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. 
  • Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). 
  • Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. 
  • Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. 
  • Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. 
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. 
  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. 
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. 
  • Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. 
  • Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. 
  • Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. 
  • Seroconversion patterns to four human rotavirus serotypes in hospitalized infants with acute rotavirus gastroenteritis. 
  • Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. 
  • Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers, April-June 2020. 
  • Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19-Nashville, Tennessee. 
  • Seroprevalence of antibodies against chikungunya virus in Singapore resident adult population. 
  • Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. 
  • Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine. 
  • Short communication: characteristics of effective immune control of simian/human immunodeficiency virus in pigtail macaques. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. 
  • Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. 
  • Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. 
  • Single-center serological surveillance of SARS-CoV-2 in pregnant patients presenting to labor and delivery. 
  • SnapShot: SARS-CoV-2 antibodies. 
  • Spatiotemporal Heterogeneity of Zika Virus Transmission in Indonesia: Serosurveillance Data from a Pediatric Population. 
  • Specificity and distribution of the determinants of the major glycoprotein (gp71) of murine oncornaviruses as detected by an in vitro cytotoxicity assay. 
  • Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection. 
  • Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. 
  • Strength through Organization: Classifying Antibody Activity against EBOV. 
  • Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. 
  • Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. 
  • Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants. 
  • Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. 
  • Structure and specific antigens of avian leukosis viruses. 
  • Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope. 
  • Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. 
  • Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. 
  • Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. 
  • Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. 
  • Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. 
  • Studies of viral antibody responses among Amish families. 
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. 
  • Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation. 
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. 
  • Swine influenza H1N1 virus induces acute inflammatory immune responses in pig lungs: a potential animal model for human H1N1 influenza virus. 
  • Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition. 
  • Systems biology of vaccination for seasonal influenza in humans. 
  • T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. 
  • Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. 
  • Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. 
  • The Mediating Role of Meaning in the Association between Stress and Health. 
  • The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. 
  • The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. 
  • The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. 
  • The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. 
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. 
  • The effect of laboratory-verified smoking on SARS-CoV-2 infection: results from the Troina sero-epidemiological survey. 
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. 
  • The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. 
  • The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. 
  • The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface. 
  • The relationship between hepatitis B surface antigen and antibody and continued drug use in narcotic dependency: a randomized controlled study. 
  • The role of Epstein-Barr virus in systemic lupus erythematosus. 
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. 
  • Therapeutic effects of diethylcarbamazine and 3'-azido-3'-deoxythymidine on feline leukemia virus lymphoma formation. 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty. 
  • Towards a population-based threshold of protection for COVID-19 vaccines. 
  • Transgenic plants expressing potato virus X ORF2 protein (p24) are resistant to tobacco mosaic virus and Ob tobamoviruses. 
  • Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. 
  • Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. 
  • Unsuspected Dengue as a Cause of Acute Febrile Illness in Children and Adults in Western Nicaragua. 
  • Unsuspected dengue and acute febrile illness in rural and semi-urban southern Sri Lanka. 
  • Using Serosurvey Data Triangulation for More Accurate Estimates of Vaccine Coverage: Measured and Modeled Coverage From Pakistan Household Surveys. 
  • Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. 
  • Vaccination with Live Attenuated Simian Immunodeficiency Virus (SIV) Protects from Mucosal, but Not Necessarily Intravenous, Challenge with a Minimally Heterologous SIV. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. 
  • Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. 
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV. 
  • Vaccine evaluation studies of replication-defective SIVsmB7. 
  • Vaccine immunogenicity in injecting drug users: a systematic review. 
  • Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. 
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. 
  • Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. 
  • Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. 
  • Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. 
  • Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. 
  • Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia. 
  • Viral infection-homograft interactions in a murine model. 
  • Viral receptor-binding site antibodies with diverse germline origins. 
  • Viral regulatory region effects on vertical transmission of polyomavirus SV40 in hamsters. 
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. 
  • Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. 
  • Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques. 
  • West Nile virus in Mexico: evidence of widespread circulation since July 2002. 
  • West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. 
  • Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? 
  • XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells. 
  • ZIKV-Specific NS1 Epitopes as Serological Markers of Acute Zika Virus Infection. 
  • Zika Virus Seropositivity in 1-4-Year-Old Children, Indonesia, 2014. 
  • Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. 
  • [Association between HSV-2 infection and serum anti-rat brain antibodies in patients with autism]. 
  • [Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)]. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor Emeritus of Pediatrics, in the School of Medicine, Pediatrics, Allergy and Immunology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Klotman, Mary E, R.J. Reynolds Distinguished Professor of Medicine, School of Medicine
  • McClain, Micah Thomas, Associate Professor of Medicine, Medicine, Infectious Diseases
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology